Herb Hurwitz
Affiliations: | 2017-2018 | Oncology | Genentech, Inc., San Francisco, CA, United States |
Google:
"Herb Hurwitz"Parents
Sign in to add mentor| Daniel S Chen | research scientist | 2017-2018 | Genentech, Inc. | |
| (Cancer Immunotherapy, GI Cancer) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yin J, Dawood S, Cohen R, et al. (2021) Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology. 13: 17588359211020547 |
| Morse M, Halperin DM, Uronis HE, et al. (2021) Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET). Journal of Clinical Oncology. 39: 369-369 |
| Uronis HE, Rushing C, Blobe GC, et al. (2021) KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma. Journal of Clinical Oncology. 39: 228-228 |
| Cremolini C, Antoniotti C, Stein A, et al. (2020) Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001225 |
| Garcia J, Hurwitz HI, Sandler AB, et al. (2020) Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 86: 102017 |
| Max Ma X, Bendell JC, Hurwitz HI, et al. (2020) Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Alvarez Secord A, Bell Burdett K, Owzar K, et al. (2020) Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Strickler JH, Rushing CN, Niedzwiecki D, et al. (2019) A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. Bmc Cancer. 19: 1032 |
| Bendell JC, Sauri T, Gracián AC, et al. (2019) The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist |
| Clarke JM, Blobe GC, Strickler JH, et al. (2019) A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology |